The results of a Phase 3 REACH study of EFAPROXYN™ (efaproxiral) plus whole brain radiation therapy in patients with brain metastases from various primary cancers as announced by Allos Therapeutics, Inc. were were reported in the June 13th edition of the British Journal of Cancer (volume 94, issue 12).
The study found that cancer patients who were sufficiently exposed to EFAPROXYN™ (efaproxiral) achieved clinically meaningful survival and response rate benefits.
A copy of the paper can be found here or you can read the full press release."These findings suggest that patients with brain metastases from non-small cell lung cancer who receive adequate exposure to efaproxiral have the potential to achieve clinically meaningful survival and response rate benefits," said Michael E. Saunders, M.D., Vice President, Clinical Development of Allos.
"The information obtained from this analysis may, in part, account for the efficacy variance observed between primary breast and NSCLC patients in the REACH study and provides important insight into the therapeutic dosing requirements for future clinical development of efaproxiral in this patient setting."
.jpg)
Comment Preview